Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy

Journal of Infectious Diseases

Volumn 184, Issue 9, 2001, Pages 1197-1201

  Domingo, Pere ^a   Matías Guiu, Xavier ^a   Pujol, Ramón M ^a   Domingo, Joan C ^b   Arroyo, Juan A ^a   Sambeat, María A ^a   Vázquez, Guillermo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIGOXIGENIN; DNA NUCLEOTIDYLEXOTRANSFERASE; GLUCOSE; INDINAVIR; INSULIN; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; TRIACYLGLYCEROL; VIRUS RNA;

ADIPOCYTE; ADULT; APOPTOSIS; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADIPOCYTES; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; BLOOD GLUCOSE; FEMALE; HIV INFECTIONS; HUMANS; IN SITU NICK-END LABELING; INDINAVIR; INSULIN; LIPODYSTROPHY; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035500311     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323805     Document Type: Article

References (17)

1. Lipodystrophy in HIV-1-infected patients
2. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
3. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
4. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor associated lipodystrophy
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. Detection of low HIV-1 RNA levels in plasma
7. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
8. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
9. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
10. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
11. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
12. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy
13. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy
14. Mitochondria and apoptosis
15. Tumor necrosis factor-α induces apoptosis of human adipose cells
16. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults